Laboratory Corporation of America Holdings (LH)

Rating: HOLD

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

Investment Thesis

The bull case — 'Bull — Re-Rate' (8% weight) — targets $478, +71% vs spot. It needs Gross Margin to surprise to the upside.

The dashboard below is the whole argument on one page: spot ($280) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural case — 'Structural — Reimbursement / In-House Testing' (20%) — targets $119, -58% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.

Key Debate

Gross Margin explains 58% of Monte Carlo outcome variance — the single variable that decides which side is right.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.42 vs analyst floor -0.04 → delta +0.46 (n=18 mgmt / 10 Q&A; 64th pctile across the S&P book, z +0.4).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 1000 articles): avg ticker sentiment +0.20 (bullish 23% / bearish 1%)

Scenario Analysis

The tree runs from a structural 'Structural — Reimbursement / In-House Testing' downside ($119) to a 'Bull — Re-Rate' bull case ($478); the probability-weighted blend (PWEV $270) is -4% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Reimbursement / In-House Testing (20%, $119). Structural impairment — reimbursement / in-house testing: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 118.87; probability: 0.2.
• Volume Recession (17%, $202). Cyclical downturn — diagnostic test volumes + reimbursement rates + advanced-test mix + M&A weakens for 1–2 years before normalising. Drivers — implied_target: 201.86; probability: 0.17.
• Base — Volume + Acquisitions (35%, $280). Mid-cycle — normalised diagnostic test volumes + reimbursement rates + advanced-test mix + M&A; disciplined capital allocation; steady returns. Drivers — implied_target: 280.36; probability: 0.35.
• Growth — Advanced-Diagnostics / M&A (20%, $378). Upside — advanced diagnostics + M&A lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 378.48; probability: 0.2.
• Bull — Re-Rate (8%, $478). Upside tail — sustained tight conditions or a structural re-rate on advanced diagnostics + M&A. Drivers — implied_target: 478.01; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $249 + scenario PWEV $270, ≈ spot); the weighted blend $226 (-19%) sits below it because the cash-flow DCF ($173) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $249 and 41% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (58% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 13x terminal FCF multiple → $173. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 14.455x) implies $260. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is wide (genuine disagreement — low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Services

This name sits in the Health Services as a diagnostics. diagnostic test volumes + reimbursement rates + advanced-test mix + M&A Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: MCK (distributors) · COR (distributors) · CAH (distributors) · DGX (diagnostics) · LH (diagnostics) · HSIC (distributors)

On the cluster's key downside — Reimbursement / Disintermediation Pressure () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_services cycle is the shared macro driver. Driver — drug/lab volumes + reimbursement + thin-margin distribution & specialty mix Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $6B + PV(terminal) $14B = EV $20B; + net cash → equity $14B ÷ diluted shares 0.08B = $173/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $228/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 6% vs WACC 8% → below WACC — the incremental build is value-dilutive.

Peer set

Peer-median fwd P/E → $260; EV/Rev → $129.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Diagnostics & Lab Services multiple (AI re-rating) (base 15x)

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 13×, FY+5 revenue $16B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

A miss on Gross Margin drops the case toward the structural target $119.

Fact / Inference / Speculation

• FACT: Spot $280; 52-week range $239–$291; engine rating HOLD; base-case target $270 (-4%).
• INFERENCE: Triangulated FV $226 (-19%). Gross Margin explains 58% of Monte Carlo outcome variance — the single variable that decides which side is right.
• SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 58% of outcome variance.

Recommendation: HOLD

Balanced: triangulated fair value $226 (-19% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (58% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).